Navigation Links
Coronado Biosciences, Inc. Announces Completion of Financings, Management Changes and Development Update
Date:11/3/2010

NEW YORK, Nov. 3, 2010 /PRNewswire/ -- Coronado Biosciences, Inc., a privately held company engaged in innovative oncology drug development, announced completion of a series of private financings in 2010, resulting in aggregate gross proceeds to the Company of approximately $21.6 million.  The Company intends to use the proceeds from these financings for general corporate purposes, including working capital, and to fund development activities for its lead product candidate, CNDO-109, including the initiation of a Phase 2 clinical trial in the US in patients with advanced acute myelogeous leukemia (AML).  Paramount BioCapital, Inc. acted as lead placement agent for the financings.

CNDO-109 is a biological product based on in-licensed technology that activates natural killer (NK) cells harvested from close relatives of cancer patients or from the patient  for the therapy of a wide-range of difficult to treat blood and solid tumor cancers.

Based on the results of a recently-completed Phase 1 open-label, uncontrolled clinical trial of CNDO-109 therapy in adult AML patients conducted at the Royal Free Hospital in London, the Company intends to file a Investigational New Drug application (IND) with the US Food and Drug Administration and to pursue a multicenter Phase 2 clinical trial for AML patients in the US, which the Company expects to commence in 2011.

Glenn L. Cooper, MD has joined the Company as Executive Chairman and Acting Chief Executive Officer, replacing R.J. Tesi, M.D., who has left the Company.  Dr. Cooper has 20 years of experience in the pharmaceutical and biotechnology industries, most recently as Chairman and Chief Executive Officer of Indevus Pharmaceuticals, which was acquired by Endo Pharmaceuticals in 2009 for an aggregate acquisition price that has the potential to reach $700 million.

Eric Rowinsky, MD, has joined the Company as Vice Chairman and will serve as a consultant with particular focus on oversight of the Company's clinical development programs. Dr. Rowinsky was Chief Medical Officer and Executive Vice President at Imclone Systems from 2005 to 2009. Dr. Rowinsky is one of the country's leading cancer drug development experts.

Gary Gemignani has joined the company as Executive Vice President, Chief Operating Officer and Chief Financial Officer. Prior to joining Coronado, Mr. Gemignani was Executive Vice President, Chief Operating Officer and Chief Financial Officer of Gentium SpA, a developer of drugs for complications of cancer therapy. Prior to that, Mr. Gemignani held management positions of increasing responsibility at Wyeth, Novartis, and Prudential Financial.

This press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements.  These forward-looking statements concern the timing, progress and results of the clinical development, regulatory processes, potential clinical trial initiations of the Company's product candidates, as well as the potential role these product candidates may play in the treatment of cancers. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. These statements are subject to various risks and uncertainties and include the Company's need for additional capital to fund its clinical development programs, the possibility that the results of clinical trials will not support the Company's claims, the possibility that the Company's development efforts relating to its product candidates will not be successful, the inability to obtain regulatory approval of the Company's product candidates, the Company's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Coronado Biosciences, Inc. Contact:

Gary Gemignani, (212) 332-1666, ggemignani@coronadobiosciences.com




'/>"/>
SOURCE Coronado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
2. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
3. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
4. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
5. Neurocrine Biosciences, Inc. Prices Common Stock Offering
6. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR
7. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
8. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
9. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
10. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
11. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/18/2017)... SAN DIEGO and BLOOMINGTON, ... Pharmaceuticals, Inc. (NASDAQ: IMMY ) ("Imprimis"), ... d/b/a Precision Lens ("Precision Lens"), today announced the ... Under the agreement, Precision Lens will deploy a ... into select geographies in the U.S., primarily focused ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Date aired: ... , “Computers are everywhere and they’re here to stay,” said Sharon Kleyne on ... and Your Health on Voice America sponsored by Nature’s Tears® EyeMist®. So she ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... that Aditya Patel M.D. has joined the revolutionary endoscopic practice under Dr. Datta. ... certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created and used ...
(Date:4/28/2017)... ... 28, 2017 , ... From April 30 to May 3, ... will host industry leaders for the annual spring Convention & Expo, called Momentum ... adapt to the issues currently affecting urgent care and on-demand healthcare. , “Momentum ...
(Date:4/28/2017)... ... 28, 2017 , ... Bill Howe started his sewer and drain company in ... Howe joined the team, the Bill Howe brand was born and they began cultivating ... giving back to the San Diego community in which they worked, lived and were ...
(Date:4/28/2017)... SALT LAKE CITY, UTAH (PRWEB) , ... April ... ... Josée Côté as Account Manager for the North East region. Côté has 20+ ... operations and consulting. Prior to Phytomer, Côté worked with an array of high-end ...
Breaking Medicine News(10 mins):